CRMD
CorMedix Inc.
$8.54
+2.15%
$670.0M
No data for this timeframe.
Vol
Market Cap$670.0M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders7 funds
Inst. Value$73.0M
Inst. Activity3 buys / 1 sells
Reddit Sentiment33° Cool
SEC Reports5
Press Releases3
Recent Activity
Jun 8, 2026
SEC
CorMedix announced that the U.S. Court of Appeals for the Federal Circuit affirmed the district court's judgment that Ne
8-K — Impact 7/10
Jun 8, 2026
announcement
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
<p align="justify">PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasd
May 14, 2026
SEC
CorMedix reported Q1 2026 revenue of $127.4M and GAAP net income of $38.6M ($0.43 diluted EPS), with DefenCath sales of
8-K — Impact 7/10
May 14, 2026
SEC
CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 diluted (30% above $0.33
PRESS-RELEASE — Impact 7/10
Feb 4, 2026
Insider
Zelnick Kaufman Beth sold 36,006 shares
Chief Legal Officer @ $0.00 ($0.00)
Feb 4, 2026
Insider
Hurlburt Elizabeth sold 36,006 shares
Chief Operating Officer @ $0.00 ($0.00)
Feb 4, 2026
Insider
Todisco Joseph sold 77,156 shares
Chief Executive Officer @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
181,106 shares ($2.1M)
Price Targets
$15.33
+77.3% upside
Strong Buy
Current $8.65
Low $13.00
Median $15.00
High $19.00
6 analysts
$13.00
$19.00
Analyst Ratings
3Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 28, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Apr 28, 2026 | Citizens | REITERATE | Market Outperform → Market Outperform |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| Apr 27, 2026 | Needham | MAINTAIN | Buy → Buy |
| Apr 27, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.27 ▼ -1.8% | $0.27 — $0.27 | -4% YoY | 1 |
| Next Q | $0.01 ▼ -89.5% | $0.01 — $0.01 | -99% YoY | 1 |
| Current FY | $0.51 ▼ -23.2% | $0.42 — $0.56 | -75% YoY | 6 |
| Next FY | $0.35 ▼ -51.4% | $0.35 — $0.35 | 1 |
Latest Reports
BULLISH
8-K
7/10
CorMedix announced that the U.S. Court of Appeals for the Federal Circuit affirmed the district court's judgment that Ne
Jun 8, 2026
BULLISH
Press
7/10
CorMedix announced that the Federal Circuit affirmed a district court ruling upholding the validity and infringement of
Jun 8, 2026
BULLISH
8-K
7/10
CorMedix reported Q1 2026 revenue of $127.4M and GAAP net income of $38.6M ($0.43 diluted EPS), with DefenCath sales of
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $52.3M | — |
| MORGAN STANLEY | $7.5M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $7.1M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $2.1M | ADD |
| BANK OF AMERICA CORP | $1.5M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 4, 2026 | Zelnick Kaufman | A | $0.00 |
| Feb 4, 2026 | Hurlburt Elizabeth | A | $0.00 |
| Feb 4, 2026 | Todisco Joseph | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
7 institutional holders with $73.0M total value (6,280,652 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,499,010 | $52.3M | 71.6% | — |
| 2 | MORGAN STANLEY | 648,762 | $7.5M | 10.3% | ADD +76.4% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 610,928 | $7.1M | 9.7% | DOUBLED +199.0% |
| 4 | TWO SIGMA INVESTMENTS, LP | 181,106 | $2.1M | 2.9% | ADD +40.9% |
| 5 | BANK OF AMERICA CORP /DE/ | 130,569 | $1.5M | 2.1% | TRIM -54.1% |
| 6 | FMR LLC | 123,777 | $1.4M | 2.0% | DOUBLED +1376.3% |
| 7 | WELLS FARGO & COMPANY/MN | 86,500 | $1.0M | 1.4% | ADD +84.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 128,555 | 181,106 | +40.9% | $2.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 284,708 | 130,569 | -54.1% | $1.5M | 2025-Q4 |
| FMR LLC | DOUBLED | 8,384 | 123,777 | +1376.3% | $1.4M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 46,884 | 86,500 | +84.5% | $1.0M | 2025-Q4 |
| UBS Group AG | DOUBLED | 275,944 | 1,090,908 | +295.3% | $12.7M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 195,455 | 584,482 | +199.0% | $6.8M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 212,803 | 284,708 | +33.8% | $3.3M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 316,963 | 128,555 | -59.4% | $1.5M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 34,684 | 46,884 | +35.2% | $545.3K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 152,200 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 27,950 | 316,963 | +1034.0% | $3.9M | 2025-Q2 |
| UBS Group AG | TRIM | 602,534 | 275,944 | -54.2% | $3.4M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 38,809 | 212,803 | +448.3% | $2.6M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 152,200 | — | $1.9M | 2025-Q2 |
| Elliott Investment Management L.P. | EXIT | 2,444,561 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | ADD | 398,849 | 703,740 | +76.4% | $4.3M | 2025-Q1 |
| UBS Group AG | ADD | 379,868 | 602,534 | +58.6% | $3.7M | 2025-Q1 |
| FMR LLC | TRIM | 21,953 | 6,818 | -68.9% | $42.0K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 134,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| Elliott Investment Management L.P. | ADD | 1,550,523 | 2,870,632 | +85.1% | $23.3M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 350,196 | 566,537 | +61.8% | $4.6M | 2024-Q4 |
| UBS Group AG | DOUBLED | 39,516 | 379,868 | +861.3% | $3.1M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 134,000 | — | $1.1M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 19,266 | 30,421 | +57.9% | $246.4K | 2024-Q4 |
| MORGAN STANLEY | ADD | 271,463 | 342,386 | +26.1% | $2.8M | 2024-Q3 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | Zelnick Kaufman Beth | Chief Legal Officer | A | 36,006 | $0.00 | $0.00 |
| Feb 4, 2026 | Hurlburt Elizabeth | Chief Operating Officer | A | 36,006 | $0.00 | $0.00 |
| Feb 4, 2026 | Todisco Joseph | Chief Executive Officer | A | 77,156 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 5 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.4/10.
BULLISH
8-K
7/10
CorMedix announced that the U.S. Court of Appeals for the Federal Circuit affirmed the district cour
Jun 8, 2026
BULLISH
8-K
7/10
CorMedix reported Q1 2026 revenue of $127.4M and GAAP net income of $38.6M ($0.43 diluted EPS), with
May 14, 2026
BULLISH
PRESS-RELEASE
7/10
CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 dilut
May 14, 2026
BULLISH
8-K
8/10
CorMedix announced positive topline results from its Phase III ReSPECT trial for REZZAYO (rezafungin
Apr 27, 2026
BULLISH
8-K
8/10
CorMedix reported strong Q4 2025 financial results with $128.6 million in revenue, driven by DefenCa
Mar 5, 2026
BULLISH
7/10
CorMedix announced that the Federal Circuit affirmed a district court ruling upholding the validity
Jun 8, 2026
BULLISH
8/10
CorMedix announced positive Phase III topline results from the ReSPECT trial, showing that rezafungi
Apr 27, 2026
BULLISH
8/10
CorMedix reported strong Q4 and full-year 2025 results, driven by $128.6M in revenue (up 312% YoY) a
Mar 5, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 3 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$15.33 mean target
+77.3% upside
Strong Buy (3.00)
$13.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $8.65 |
| Target Low | $13.00 |
| Target Mean | $15.33 |
| Target Median | $15.00 |
| Target High | $19.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.27 | $0.27 | $0.27 | -3.6% | -1.8% | 1↑ 0↓ | $0.1B | 138.9% | 1 |
| Next Q 2026-09-30 |
$0.01 | $0.01 | $0.01 | -99.3% | -89.5% | — | $0.1B | -48.4% | 1 |
| Current FY 2026-12-31 |
$0.51 | $0.42 | $0.56 | -75.2% | -23.2% | 3↑ 3↓ | $0.3B | 6.7% | 6 |
| Next FY 2027-12-31 |
$0.35 | $0.35 | $0.35 | — | -51.4% | 0↑ 1↓ | $0.3B | -13.8% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.270 | |
| 7d ago | $0.265 | +0.005 |
| 30d ago | $0.275 | -0.005 |
| 60d ago | $0.275 | -0.005 |
| 90d ago | $0.517 | -0.247 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 28, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 28, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 27, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 27, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 11, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 8, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 5, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 5, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
$CRMD - *Leans in*
▲ 1
💬 1
⚡ 0.5
Jun 8, 2026
announcement
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
<p align="justify">PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States C
May 19, 2026
short_volume
Short Volume: CRMD — 64.4% short (0.4M / 0.6M)
Short: 398,432 | Exempt: 310 | TRF Vol: 618,606 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CRMD — 58.2% short (0.5M / 0.8M)
Short: 453,501 | Exempt: 1,624 | TRF Vol: 779,475 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
other
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
<p align="justify">PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be p
May 15, 2026
short_volume
Short Volume: CRMD — 61.2% short (0.5M / 0.9M)
Short: 532,019 | Exempt: 5,490 | TRF Vol: 870,007 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>‒ Q1 2026 Net Revenue of </em><em>$127.4 million</em><em> ‒</em></p>
May 14, 2026
earnings_calendar
CRMD Q1 2026 Earnings Scheduled — 2026-05-14
May 11, 2026
short_volume
Short Volume: CRMD — 55.2% short (0.3M / 0.5M)
Short: 281,629 | Exempt: 2,224 | TRF Vol: 509,777 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
CRMD Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
earnings
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
<p align="justify">PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its f
May 4, 2026
earnings_calendar
CRMD Q1 2026 Earnings Scheduled — 2026-05-04
Apr 27, 2026
fda
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
<p align="center">– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –
Apr 27, 2026
short_volume
Short Volume: CRMD — 60.3% short (0.4M / 0.7M)
Short: 397,582 | Exempt: 448 | TRF Vol: 659,306 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: CRMD — 58.7% short (0.3M / 0.5M)
Short: 311,596 | Exempt: 14,678 | TRF Vol: 530,642 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
other
CorMedix to Participate in Needham Virtual Healthcare Conference
<p align="justify">PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on